The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Calithera Biosciences, Inc. | Common Stock | 13089P101 | 5,290 | 2,426,702 | SH | SOLE | 2,426,702 | 0 | 0 | ||
Karyopharm Therapeutics, Inc. | Common Stock | 48576U106 | 13,170 | 2,263,006 | SH | SOLE | 2,263,006 | 0 | 0 | ||
Mereo BioPharma Group PLC | ADS | 589492107 | 621 | 256,734 | SH | SOLE | 256,734 | 0 | 0 | ||
Tandem Diabetes, Inc. | Common Stock | 875372203 | 119,380 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 |